Genzyme and Merck agree cancer assay licence:
This article was originally published in Clinica
Genzyme Molecular Oncology has licensed non-exclusive rights to Merck for Genzyme's methods of assaying small molecule compounds for their action against the cancer-related protein, MDM2. Merck will pay up to $8 million in milestone payments if it can develop a therapeutic product through use of this assay.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.